Astec LifeSciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Revenue growth above 20%Net loss reportedEBITDA margin expansionDebt to equity above the thresholdResults View source PDF Explain this filing

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.1%Reaction day

₹893.50

prior close

₹870.65

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.2%-4.9% vs market

Pesticides & Agrochemicals peers, median of 25sector+0.5%-6.6% vs sector

On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 6.6 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-3.2

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.1-1.2-4.9+0.5-6.6

Next day

-2.0+0.3-2.2+3.3-5.3

-3.0+0.6-3.5+4.4-7.3

-0.1-0.1+0.0+3.8-3.9

-1.1-1.7+0.7+1.3-2.3

-1.4-1.2-0.2+0.8-2.2

-5.8-2.6-3.1-0.9-4.9

15d

-7.1-1.0-6.1-5.4-1.7

-3.7-3.9+0.2-7.3+3.5

-9.3-4.2-5.2-10.0+0.6

-23.4-0.7-22.8-12.6-10.9

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astec LifeSciences, a Godrej-group agrochemical company, reported Q1 FY26 results with revenue from operations rising 31% year-on-year to Rs 9,108.21 lakh from Rs 6,937.25 lakh. Despite the revenue growth, the company posted a standalone net loss of Rs 3,305.64 lakh, although this was narrower than the Rs 3,973.69 lakh loss in Q1 FY25. Operating margin improved sharply from -66.67% to -12.06%, and net loss margin also narrowed from -57.28% to -36.29%. However, key financial health metrics are weak: debt-equity ratio has climbed to 2.96 (from 1.58 a year ago), debt service coverage and interest coverage ratios are negative, current ratio is 0.78 with negative working capital. The statutory auditor (BSR & Co. LLP) issued an unmodified review opinion. A Rs 249.35 crore rights issue at Rs 890 per share (1:7 ratio) is currently open and closes on the same day (July 28, 2025).

Likely market impact

The strong revenue growth and improving margins signal a business recovery, but persistent losses, surging leverage (D/E of 2.96), and negative debt service coverage keep the stock risky. The rights issue outcome is critical — proceeds are needed to shore up the balance sheet. Short-term stock movement is likely to depend heavily on rights issue subscription levels.